Agilent Technologies’ Exome Target-Enrichment System to Analyze 1,500 Samples in Erasmus Genetic Population Study
News Mar 08, 2012
The researchers are studying reduced heterozygosity exhibited by residents of one Dutch village compared to the general population, and any relationship this has with risk factors for type-2 diabetes or cardiovascular disease. In this portion of the project, exomes from 1,500 samples will be sequenced.
“The genetically isolated population of the study is ideal for the discovery of new genetic variants related to complex disorders,” said Wilfred van IJcken, head of the genomics core facility at Erasmus Medical Center. “We are halfway through this sequencing project and are very pleased with the results so far.
The newly designed v4 exome-capture platform needs only 4 Gbp, which is financially attractive because more exomes can be analyzed. Furthermore, we have been pleasantly surprised by the quality of the data.”
“We are excited by the potential implementation of exome sequencing for clinical diagnostics as well,” van IJcken added. “We hope that this approach will be one of the favorites to succeed.”
“As interest continues to grow in exome sequencing,” said Robert Schueren, Agilent vice president and general manager, Genomics, “we’ve put a lot of effort into providing a complete, streamlined exome target-enrichment workflow from sample prep to sequencing.”
SureSelect XT includes SureSelect biotinylated RNA library “baits,” hybridization buffers, and optimized gDNA prep and library prep kits.
The investigators have produced 50 exomes per week during each of three consecutive months, including analysis. The workflow uses the Agilent Bravo liquid-handling platform to automate DNA library prep and in-solution enrichment.
The SureSelect portfolio provides a complete and customizable target-enrichment platform. Since it was introduced in 2009, SureSelect has been instrumental in more than 230 published studies covering research into a wide range of heritable disorders and complex diseases. There are now more than 23 products in the SureSelect portfolio, including a full range of catalog and custom products. The Agilent Bravo automated liquid-handling platform is the fastest and most versatile small footprint liquid-handling system available.
Enterome and Nestlé Health Sciences Launch New Diagnostics CompanyNews
Enterome and Nestlé Health Sciences join to create Microbiome Diagnostics Partners, a company that will enable the development and diagnostics for multiple diseases including inflammatory bowel diseases (IBD) and liver diseases.READ MORE
Material From Shellfish Boosts Sensitivity of Diagnostic TestsNews
By adding polydopamine at a key step, the sensitivity of diagnostic tests and bioassays can be increased by as many as 100 to 1,000 times.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018